<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03924427</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-066</org_study_id>
    <nct_id>NCT03924427</nct_id>
  </id_info>
  <brief_title>An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis</brief_title>
  <official_title>An Open-Label, Single-arm, Multi-Center, Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Japanese Subjects With Moderate-to-Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate BMS-986165 given to Japanese participants with
      moderate-to-severe psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Anticipated">November 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who achieve static Physician's Global Assessment (sPGA) score of 0 to 1 response</measure>
    <time_frame>16 weeks</time_frame>
    <description>The sPGA score is the investigator's assessment of a participant's psoriasis lesions at a given point in time. Overall lesions are graded and averaged for thickness, erythema, and scaling based on a 0 (normal) to 4 (severe) scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who achieve PASI 75 (75% reduction in Psoriasis Area and Severity Index)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The PASI is a scoring system used by investigators to grade the severity and extent of psoriatic lesions. In the PASI system, the body is divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved and scored for erythema, induration, and scaling to generate a composite PASI score that ranges from 0 (normal) to 72 (most severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve sPGA score of 0 or 1 response</measure>
    <time_frame>52 weeks</time_frame>
    <description>The sPGA score is the investigator's assessment of a participant's psoriasis lesions at a given point in time. Overall lesions are graded and averaged for thickness, erythema, and scaling based on a 0 (normal) to 4 (severe) scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve PASI 75</measure>
    <time_frame>52 weeks</time_frame>
    <description>The PASI is a scoring system used by investigators to grade the severity and extent of psoriatic lesions. In the PASI system, the body is divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved and scored for erythema, induration, and scaling to generate a composite PASI score that ranges from 0 (normal) to 72 (most severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve PASI 90</measure>
    <time_frame>52 weeks</time_frame>
    <description>At least 90% improvement in PASI scores from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve PASI 100</measure>
    <time_frame>52 weeks</time_frame>
    <description>100% improvement in PASI scores from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology Criteria (ACR20) response in participants with psoriatic arthritis</measure>
    <time_frame>52 weeks</time_frame>
    <description>Assessed as a proportion of participants meeting ACR20 criteria, where a responder is defined if the following 3 conditions are met:
≥ 20% improvement from baseline in the number of tender joints (68 joint count)
≥ 20% improvement from baseline in the number of swollen joints (66 joint count)
≥ 20% improvement from baseline in 3 of the following 5 domains:
Patient Global Assessment of joint disease (measured on a Visual Analogue Scale (VAS), 0-100)
Physician Global Assessment of joint disease (measured on a VAS, 0-100)
Patient assessment of joint pain (measured on a VAS, 0-100)
Health Assessment Questionnaire- Disability Index (HAQ-DI)
high-sensitivity C-reactive protein (hs-CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the ACR core set in participants with psoriatic arthritis</measure>
    <time_frame>52 weeks</time_frame>
    <description>Tender and swollen joint counts
Patient global assessment of joint disease
Physician global assessment of joint disease
Patient assessment of joint pain
HAQ-DI
hs-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Psoriasis Symptoms and Signs Diary (PSSD) score</measure>
    <time_frame>52 weeks</time_frame>
    <description>PSSD symptom score of 0 assessed as a proportion of participants with a PSSD symptom score of 0 among participants with a baseline PSSD symptom score ≥ 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve Scalp Specific (ss)-PGA score 0 or 1 among participants with a baseline ss-PGA score ≥3</measure>
    <time_frame>52 weeks</time_frame>
    <description>Severity of scalp psoriasis lesions as measured by ss-PGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve PGA-F score 0 or 1 among participants with a baseline PGA-F score ≥3</measure>
    <time_frame>52 weeks</time_frame>
    <description>Severity of fingernail psoriasis as measured by PGA-F among participants with a baseline PGA-F score &gt;= 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve palmoplantar (pp)-PGA score of 0 or 1 among participants with a baseline pp-PGA score ≥3</measure>
    <time_frame>52 weeks</time_frame>
    <description>Severity of palmoplantar psoriasis as measured by pp-PGA.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>BMS-986165</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Given daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Oral tablet administration</description>
    <arm_group_label>BMS-986165</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

        a. For participants with plaque psoriasis: i. Stable plaque psoriasis for at least 6 months
        ii. Moderate to severe disease iii. Candidate for phototherapy or systemic therapy b.
        Additional protocol-specified inclusion criteria apply for subjects with psoriatic
        arthritis, erythrodermic psoriasis, or generalized pustular psoriasis

        Exclusion Criteria:

          1. Guttate, inverse, or drug-induced psoriasis at Screening or Baseline

          2. History of recent infection

          3. Prior exposure to BMS-986165

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital</name>
      <address>
        <city>Toon-Shi</city>
        <state>Ehime</state>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Occupational and Environmental Health, Japan</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>807-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Skin Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>6500017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>0208505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara City</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>2360004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Yokohama Medical Center</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>2458575</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kochi Medical School Hospital</name>
      <address>
        <city>Nakoku</city>
        <state>Kochi</state>
        <zip>783-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital - Kyoto Preferctural University of Medicine</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <state>MIE</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>3908621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>7108602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>5458586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University Hospital</name>
      <address>
        <city>Itabashi</city>
        <state>Tokyo</state>
        <zip>173-8605</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei University Hospital</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Shinagawa</city>
        <state>Tokyo</state>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>1600023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Community Health Care Organization Tokyo Yamate Medical Center</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Life Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>550-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-986165</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

